CGS 21680

Drug Profile

CGS 21680

Alternative Names: CGS 21680C

Latest Information Update: 14 May 1997

Price : $50

At a glance

  • Originator Novartis
  • Class Antiepileptic drugs; Antihypertensives; Antiparkinsonians; Anxiolytics; Neuroprotectants
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension; Myocardial ischaemia

Most Recent Events

  • 14 May 1997 Discontinued-Preclinical for Hypertension in Switzerland (Unknown route)
  • 14 May 1997 Discontinued-Preclinical for Myocardial ischaemia in Switzerland (Unknown route)
  • 16 Jan 1996 Discontinued-Preclinical for Myocardial ischaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top